Hang Quach
Hematology — St Vincent's Hospital, Australia
Hang Quach
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology - Cardiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Hang Quach is a haematologist specialising in multiple myeloma. She is Professor of Haematology at the University of Melbourne and serves as Head of Department and Director of Research at St Vincent’s Hospital Melbourne (SVHM). She leads the SVHM Myeloma Program and oversees its clinical trials unit, which runs over 135 active phase I to III clinical trials investigating novel therapies in haematological malignancies.
Professor Quach currently serves as Co-Chair of the Myeloma Working Group of the Australasian Lymphoma and Leukaemia Group (ALLG), Deputy Chair of the Myeloma Scientific Advisory Group (MSAG) for Myeloma Australia, and a Steering Committee Member of the Australasian Myeloma Research Consortium (AMaRC).
Her clinical research focuses on novel therapeutics for multiple myeloma and the development of regionally relevant trials that translate into practice across the Asia-Pacific (APAC) region
Organizations
Career arc: 2005 - 2026
Number : 428
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 41
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study of Gammagard Liquid (Immune Globulin Infusion 10 ) to Prevent Infections in Adults With Multiple Myeloma NCT06980480 — cells, safety, pharmaceutical preparations, drug therapy, immunoglobulins, multiple myeloma, therapeutics, globulins, b-lymphocytes, infections | Phase 3 | Recruiting | 2026 |
| A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation NCT06045806 — cells, safety, microscopy, electron, scanning transmission, cyclophosphamide, stem cells, maintenance, multiple myeloma, lenalidomide, therapeutics, cell transplantation, stem cell transplantation, transplantation | Phase 3 | Active not recruiting | 2023 |
| Study of ISB 2001 in Relapsed Refractory Multiple Myeloma (TRIgnite 1) NCT05862012 — injections, multiple myeloma | Phase 1 | Recruiting | 2023 |
| A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and or Refractory Multiple Myeloma NCT05704049 — administration, oral, powders, methylprednisolone, pharmaceutical preparations, dexamethasone, administration, intravenous, tablets, solutions, acetaminophen, multiple myeloma, therapeutics, diphenhydramine | Phase 2 | Active not recruiting | 2023 |
| A Study Comparing Teclistamab Monotherapy Versus Pomalidomide Bortezomib Dexamethasone (PVd) or Carfilzomib Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma NCT05572515 — dexamethasone, bortezomib, multiple myeloma, antibodies, monoclonal, lenalidomide, therapeutics | Phase 3 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map